BRPI1008692A2 - moléculas de anticorpos tendo especificidade para ox40 humano. - Google Patents

moléculas de anticorpos tendo especificidade para ox40 humano.

Info

Publication number: BRPI1008692A2
Authority: BR; Brazil
Prior art keywords: specificity; human; antibody molecules; antibody; molecules
Prior art date: 2009-02-17

Application number

BRPI1008692A

Other languages

English (en)

Inventor

Alastair Griffiths Lawson

Andrew George Popplewell

Andrew Malcolm Nesbitt

Diana Shpektor

Stephen Graham Shaw

Yi Zhang

Original Assignee

Ucb Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-17

Filing date

2010-02-17

Publication date

2016-03-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008692(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-02-17 Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa

2016-03-08 Publication of BRPI1008692A2 publication Critical patent/BRPI1008692A2/pt

2020-10-27 Publication of BRPI1008692B1 publication Critical patent/BRPI1008692B1/pt

2021-05-25 Publication of BRPI1008692B8 publication Critical patent/BRPI1008692B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)

BRPI1008692A 2009-02-17 2010-02-17 anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão BRPI1008692B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15303809P	2009-02-17	2009-02-17
US61/153,038		2009-02-17
PCT/US2010/024377 WO2010096418A2 (en)	2009-02-17	2010-02-17	Antibody molecules having specificity for human ox40

Publications (3)

Publication Number	Publication Date
BRPI1008692A2 true BRPI1008692A2 (pt)	2016-03-08
BRPI1008692B1 BRPI1008692B1 (pt)	2020-10-27
BRPI1008692B8 BRPI1008692B8 (pt)	2021-05-25

Family

ID=42634416

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1008692A BRPI1008692B8 (pt)	2009-02-17	2010-02-17	anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão

Country Status (34)

Country	Link
US (3)	US8614295B2 (pt)
EP (1)	EP2398498B1 (pt)
JP (2)	JP5782385B2 (pt)
KR (1)	KR101761929B1 (pt)
CN (1)	CN102741287B (pt)
AR (1)	AR075504A1 (pt)
AU (1)	AU2010216152B2 (pt)
BR (1)	BRPI1008692B8 (pt)
CA (1)	CA2751477C (pt)
CL (1)	CL2011001994A1 (pt)
CO (1)	CO6410312A2 (pt)
CY (1)	CY1121431T1 (pt)
DK (1)	DK2398498T3 (pt)
EA (1)	EA037792B1 (pt)
ES (1)	ES2699716T3 (pt)
HR (1)	HRP20181932T1 (pt)
HU (1)	HUE042114T2 (pt)
IL (1)	IL214282A (pt)
LT (1)	LT2398498T (pt)
MA (1)	MA33122B1 (pt)
MX (1)	MX2011008697A (pt)
MY (1)	MY157473A (pt)
NZ (1)	NZ594315A (pt)
PE (1)	PE20120211A1 (pt)
PL (1)	PL2398498T3 (pt)
PT (1)	PT2398498T (pt)
SG (3)	SG2014014708A (pt)
SI (1)	SI2398498T1 (pt)
TN (1)	TN2011000374A1 (pt)
TW (1)	TWI476281B (pt)
UA (1)	UA107341C2 (pt)
UY (1)	UY32451A (pt)
WO (1)	WO2010096418A2 (pt)
ZA (1)	ZA201105500B (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT2398498T (lt) *	2009-02-17	2019-01-10	Ucb Biopharma Sprl	Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
KR101704865B1 (ko)	2010-08-23	2017-02-09	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	항-ox40 항체 및 그의 용도
US9428567B2 (en)	2010-12-22	2016-08-30	The Board Of Trustees Of The Leland Stanford Junior University	Antagonists of interleukin-2 receptor
CA3158257A1 (en) *	2011-07-11	2013-01-17	Ichnos Sciences SA	Antibodies that bind to ox40 and their uses
KR101685262B1 (ko) *	2011-08-23	2016-12-21	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	항-ｏｘ４０ 항체 및 이의 사용 방법
GB201116092D0 (en)	2011-09-16	2011-11-02	Bioceros B V	Antibodies and uses thereof
SI2776466T1 (sl) *	2011-11-11	2017-12-29	Ucb Biopharma Sprl	Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
UA112203C2 (uk) *	2011-11-11	2016-08-10	Юсб Фарма С.А.	Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
WO2013086419A1 (en) *	2011-12-09	2013-06-13	California Institute Of Technology	Polymer scaffolds and their use in the treatment of vision loss
ES2715673T3 (es)	2012-12-03	2019-06-05	Bristol Myers Squibb Co	Mejora de la actividad anticancerosa de proteínas de fusión FC inmunomoduladoras
DK2976361T3 (en)	2013-03-18	2018-10-01	Biocerox Prod Bv	HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
WO2015042707A1 (en)	2013-09-24	2015-04-02	Medicenna Therapeutics Pte Ltd	Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
EP3322443A1 (en) *	2015-07-13	2018-05-23	Yeda Research and Development Co. Ltd	Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
KR101819135B1 (ko) *	2014-03-18	2018-01-18	한국과학기술원	당화 vegf 디코이 수용체 융합 단백질
KR20160146747A (ko)	2014-03-31	2016-12-21	제넨테크, 인크.	항혈관신생제 및 ox40 결합 효능제를 포함하는 조합 요법
CA2946398A1 (en)	2014-04-24	2015-10-29	The Board Of Trustees Of The Leland Stanford Junior University	Superagonists, partial agonists and antagonists of interleukin-2
EA201692458A1 (ru)	2014-05-28	2017-06-30	Агенус Инк.	Анти-gitr антитела и способы их применения
TW201619200A (zh)	2014-10-10	2016-06-01	麥迪紐有限責任公司	人類化抗－ｏｘ４０抗體及其用途
ES2755527T3 (es)	2015-01-08	2020-04-22	BioNTech SE	Agentes agonistas de unión al receptor de TNF
US9512229B2 (en)	2015-03-03	2016-12-06	Kymab Limited	Synergistic combinations of OX40L antibodies for the treatment of GVHD
EP3265123B1 (en)	2015-03-03	2022-10-26	Kymab Limited	Antibodies, uses & methods
WO2016145085A2 (en)	2015-03-09	2016-09-15	Celldex Therapeutics, Inc.	Cd27 agonists
GB201506868D0 (en) *	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method for protein purification
MX2017014188A (es)	2015-05-07	2018-04-10	Agenus Inc	Anticuerpos anti-ox40 y metodos para su uso.
TWI732760B (zh)	2015-05-29	2021-07-11	美商必治妥美雅史谷比公司	抗ｏｘ４０抗體及其用途
WO2017055398A2 (en)	2015-10-02	2017-04-06	F. Hoffmann-La Roche Ag	Bispecific antibodies specific for a costimulatory tnf receptor
JP6771551B2 (ja) *	2015-10-15	2020-10-21	ディンフーバイオターゲットカンパニーリミテッド	抗ｏｘ４０抗体及びその応用
SG11201804265XA (en)	2015-12-02	2018-06-28	Agenus Inc	Antibodies and methods of use thereof
SG11201805422WA (en)	2016-01-11	2018-07-30	Inhibrx Inc	Multivalent and multispecific ox40-binding fusion proteins
WO2017134292A1 (en) *	2016-02-04	2017-08-10	Glenmark Pharmaceuticals S.A.	Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
JP7461741B2 (ja)	2016-06-20	2024-04-04	カイマブ・リミテッド	抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
EP3494139B1 (en)	2016-08-05	2022-01-12	F. Hoffmann-La Roche AG	Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
SI3347379T1 (sl)	2016-08-17	2020-04-30	Compugen Ltd.	ANTI-TIGIT protitelesa, ANTI-PVRIG protitelesa in njihove kombinacije
EP3534947A1 (en)	2016-11-03	2019-09-11	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MA46770A (fr)	2016-11-09	2019-09-18	Agenus Inc	Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
EP3558363A1 (en)	2016-12-21	2019-10-30	Amgen Inc.	Anti-tnf alpha antibody formulations
CN110799213A (zh)	2017-06-01	2020-02-14	康姆普根有限公司	三联组合抗体疗法
US11542312B2 (en)	2017-06-19	2023-01-03	Medicenna Therapeutics, Inc.	IL-2 superagonists in combination with anti-PD-1 antibodies
WO2019173780A2 (en) *	2018-03-08	2019-09-12	Magenta Therapeutics, Inc.	Anti-cd252 antibodies, conjugates, and methods of use
AU2019287765A1 (en)	2018-06-15	2021-01-07	Flagship Pioneering Innovations V, Inc.	Increasing immune activity through modulation of postcellular signaling factors
EP3837285A1 (en)	2018-08-13	2021-06-23	Inhibrx, Inc.	Ox40-binding polypeptides and uses thereof
EP3860653A1 (en)	2018-10-05	2021-08-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and systems for controlling the agonistic properties of antibody variable domains by light
US10442866B1 (en) *	2019-01-23	2019-10-15	Beijing Mabworks Biotech Co. Ltd	Antibodies binding OX40 and uses thereof
WO2020227159A2 (en)	2019-05-03	2020-11-12	Flagship Pioneering Innovations V, Inc.	Methods of modulating immune activity
EP3766481A1 (en) *	2019-07-19	2021-01-20	Ichnos Sciences SA	Liquid antibody formulation
WO2021127217A1 (en)	2019-12-17	2021-06-24	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CA3162705A1 (en)	2019-12-17	2021-06-24	Amgen Inc.	Dual interleukin-2 /tnf receptor agonist for use in therapy
EP4172323A1 (en)	2020-06-29	2023-05-03	Flagship Pioneering Innovations V, Inc.	Viruses engineered to promote thanotransmission and their use in treating cancer
CN116635064A (zh)	2020-12-18	2023-08-22	世纪治疗股份有限公司	具有适应性受体特异性的嵌合抗原受体系统
EP4313109A1 (en)	2021-03-31	2024-02-07	Flagship Pioneering Innovations V, Inc.	Thanotransmission polypeptides and their use in treating cancer
EP4363059A1 (en)	2021-06-29	2024-05-08	Flagship Pioneering Innovations V, Inc.	Immune cells engineered to promote thanotransmission and uses thereof
WO2023064958A1 (en)	2021-10-15	2023-04-20	Compugen Ltd.	Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
EP4507779A1 (en)	2022-04-14	2025-02-19	Institut National de la Santé et de la Recherche Médicale	Methods for controlling the tumor cell killing by light
US20240174732A1 (en)	2022-10-05	2024-05-30	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
US12195546B2 (en)	2022-12-19	2025-01-14	Sanofi	CD28/OX40 bispecific antibodies
WO2024151687A1 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
WO2025076474A1 (en) *	2023-10-06	2025-04-10	Ichnos Sciences SA	Affinity matured anti-ox40 antibodies and use thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
DK336987D0 (da)	1987-07-01	1987-07-01	Novo Industri As	Immobiliseringsmetode
GB8719042D0 (en)	1987-08-12	1987-09-16	Parker D	Conjugate compounds
US5677425A (en)	1987-09-04	1997-10-14	Celltech Therapeutics Limited	Recombinant antibody
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
EP0768377A1 (en)	1988-09-02	1997-04-16	Protein Engineering Corporation	Generation and selection of recombinant varied binding proteins
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5750373A (en)	1990-12-03	1998-05-12	Genentech, Inc.	Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
WO1991010737A1 (en)	1990-01-11	1991-07-25	Molecular Affinities Corporation	Production of antibodies using gene libraries
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ATE139258T1 (de)	1990-01-12	1996-06-15	Cell Genesys Inc	Erzeugung xenogener antikörper
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
CA2090126C (en)	1990-08-02	2002-10-22	John W. Schrader	Methods for the production of proteins with a desired function
ES2108048T3 (es)	1990-08-29	1997-12-16	Genpharm Int	Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
DK1471142T3 (da)	1991-04-10	2009-03-09	Scripps Research Inst	Heterodimere receptor-biblioteker under anvendelse af fagemider
GB9112536D0 (en)	1991-06-11	1991-07-31	Celltech Ltd	Chemical compounds
GB9113120D0 (en)	1991-06-18	1991-08-07	Kodak Ltd	Photographic processing apparatus
GB9120467D0 (en)	1991-09-26	1991-11-06	Celltech Ltd	Anti-hmfg antibodies and process for their production
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5821332A (en)	1993-11-03	1998-10-13	The Board Of Trustees Of The Leland Stanford Junior University	Receptor on the surface of activated CD4+ T-cells: ACT-4
EP0733070A1 (en)	1993-12-08	1996-09-25	Genzyme Corporation	Process for generating specific antibodies
ES2247204T3 (es)	1994-01-31	2006-03-01	Trustees Of Boston University	Bancos de anticuerpos policlonales.
US6242566B1 (en) *	1994-02-10	2001-06-05	Board Of Trustees Of The Leland Stanford Junior University	Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
FR2716640B1 (fr)	1994-02-28	1996-05-03	Procedes Machines Speciales	Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja)	1996-01-24	1999-11-15	チッソ株式会社	アクリロキシプロピルシランの製造方法
US5980898A (en)	1996-11-14	1999-11-09	The United States Of America As Represented By The U.S. Army Medical Research & Material Command	Adjuvant for transcutaneous immunization
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
GB9812545D0 (en)	1998-06-10	1998-08-05	Celltech Therapeutics Ltd	Biological products
GB0123276D0 (en) *	2001-09-27	2001-11-21	Imp College Innovations Ltd	Uses of agents that bind immune-system components
US6908963B2 (en)	2001-10-09	2005-06-21	Nektar Therapeutics Al, Corporation	Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0124317D0 (en) *	2001-10-10	2001-11-28	Celltech R&D Ltd	Biological products
GB0129105D0 (en)	2001-12-05	2002-01-23	Celltech R&D Ltd	Expression control using variable intergenic sequences
US20040009174A1 (en)	2001-12-18	2004-01-15	Arndt Gregory Martin	Method of treating asthma
US7291331B1 (en) *	2002-09-11	2007-11-06	La Jolla Institute For Allergy And Immunology	Methods of treating OX40 medicated recall immune responses
US20040146948A1 (en)	2002-10-18	2004-07-29	Centenary Institute Of Cancer Medicine And Cell Biology	Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
ES2374068T3 (es)	2002-12-03	2012-02-13	Ucb Pharma, S.A.	Ensayo para identificar células productoras de anticuerpos.
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
GB0312481D0 (en)	2003-05-30	2003-07-09	Celltech R&D Ltd	Antibodies
US7989594B2 (en)	2003-07-01	2011-08-02	Celltech R & D Limited	Modified antibody fab fragments
GB0315457D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
GB0315450D0 (en)	2003-07-01	2003-08-06	Celltech R&D Ltd	Biological products
ITRM20030601A1 (it) *	2003-12-24	2005-06-25	Lay Line Genomics Spa	Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
GB0411186D0 (en)	2004-05-19	2004-06-23	Celltech R&D Ltd	Biological products
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
CA2528903C (en) *	2004-12-20	2008-01-15	Honda Motor Co., Ltd.	Braking device for motorcycle
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
ITRM20050290A1 (it)	2005-06-07	2006-12-08	Lay Line Genomics Spa	Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
GB0513852D0 (en)	2005-07-06	2005-08-10	Celltech R&D Ltd	Biological products
GB0514779D0 (en)	2005-07-19	2005-08-24	Celltech R&D Ltd	Biological products
TWI461436B (zh) *	2005-11-25	2014-11-21	Kyowa Hakko Kirin Co Ltd	人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2007065433A2 (en)	2005-12-05	2007-06-14	Symphogen A/S	Anti-orthopoxvirus recombinant polyclonal antibody
EP2010207A4 (en)	2006-03-22	2009-12-02	Imp Innovations Ltd	COMPOSITIONS AND METHODS RELATING TO THE MODULATION OF COMPONENTS OF THE IMMUNE SYSTEM
US20070224627A1 (en)	2006-03-23	2007-09-27	Lawrence Horowitz	Facilitation of translocation of molecules through the gastrointestinal tract
US20100136030A1 (en) *	2007-02-27	2010-06-03	Lamhamedi-Cherradi Salah-Eddine	Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
EP2535349A1 (en)	2007-09-26	2012-12-19	UCB Pharma S.A.	Dual specificity antibody fusions
CA2707773C (en)	2007-12-14	2017-01-10	Pfizer Inc.	Binding molecules to the human ox40 receptor
LT2398498T (lt) *	2009-02-17	2019-01-10	Ucb Biopharma Sprl	Antikūno molekulės, pasižyminčios specifiškumu žmogaus ox40
US20120283415A1 (en) *	2009-09-10	2012-11-08	Ucb Pharma S.A.	Multivalent Antibodies
GB0920127D0 (en) *	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
GB201000467D0 (en) *	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
CA3158257A1 (en) *	2011-07-11	2013-01-17	Ichnos Sciences SA	Antibodies that bind to ox40 and their uses
UA112203C2 (uk) *	2011-11-11	2016-08-10	Юсб Фарма С.А.	Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини

2010
- 2010-02-17 LT LTEP10744211.3T patent/LT2398498T/lt unknown
- 2010-02-17 PE PE2011001494A patent/PE20120211A1/es not_active Application Discontinuation
- 2010-02-17 JP JP2011551173A patent/JP5782385B2/ja not_active Expired - Fee Related
- 2010-02-17 NZ NZ594315A patent/NZ594315A/xx not_active IP Right Cessation
- 2010-02-17 WO PCT/US2010/024377 patent/WO2010096418A2/en active Application Filing
- 2010-02-17 SG SG2014014708A patent/SG2014014708A/en unknown
- 2010-02-17 UA UAA201111078A patent/UA107341C2/uk unknown
- 2010-02-17 PL PL10744211T patent/PL2398498T3/pl unknown
- 2010-02-17 MX MX2011008697A patent/MX2011008697A/es active IP Right Grant
- 2010-02-17 AU AU2010216152A patent/AU2010216152B2/en not_active Ceased
- 2010-02-17 ES ES10744211T patent/ES2699716T3/es active Active
- 2010-02-17 SG SG2011057528A patent/SG173620A1/en unknown
- 2010-02-17 PT PT10744211T patent/PT2398498T/pt unknown
- 2010-02-17 KR KR1020117021615A patent/KR101761929B1/ko not_active Expired - Fee Related
- 2010-02-17 SI SI201031802T patent/SI2398498T1/sl unknown
- 2010-02-17 US US12/706,993 patent/US8614295B2/en active Active
- 2010-02-17 UY UY0001032451A patent/UY32451A/es not_active Application Discontinuation
- 2010-02-17 EA EA201171060A patent/EA037792B1/ru unknown
- 2010-02-17 MY MYPI2011003526A patent/MY157473A/en unknown
- 2010-02-17 HU HUE10744211A patent/HUE042114T2/hu unknown
- 2010-02-17 BR BRPI1008692A patent/BRPI1008692B8/pt not_active IP Right Cessation
- 2010-02-17 DK DK10744211.3T patent/DK2398498T3/en active
- 2010-02-17 AR ARP100100457A patent/AR075504A1/es active IP Right Grant
- 2010-02-17 CN CN201080017854.0A patent/CN102741287B/zh not_active Expired - Fee Related
- 2010-02-17 CA CA2751477A patent/CA2751477C/en active Active
- 2010-02-17 SG SG10201505038TA patent/SG10201505038TA/en unknown
- 2010-02-17 MA MA34167A patent/MA33122B1/fr unknown
- 2010-02-17 HR HRP20181932TT patent/HRP20181932T1/hr unknown
- 2010-02-17 EP EP10744211.3A patent/EP2398498B1/en active Active
- 2010-02-22 TW TW099104929A patent/TWI476281B/zh not_active IP Right Cessation
2011
- 2011-07-25 IL IL214282A patent/IL214282A/en active IP Right Grant
- 2011-07-26 ZA ZA2011/05500A patent/ZA201105500B/en unknown
- 2011-08-02 TN TN2011000374A patent/TN2011000374A1/fr unknown
- 2011-08-08 CO CO11100099A patent/CO6410312A2/es active IP Right Grant
- 2011-08-16 CL CL2011001994A patent/CL2011001994A1/es unknown
2013
- 2013-08-22 US US13/973,189 patent/US9428570B2/en active Active
2015
- 2015-03-26 JP JP2015063849A patent/JP2015171362A/ja active Pending
2016
- 2016-08-19 US US15/242,135 patent/US10017575B2/en active Active
2018
- 2018-12-04 CY CY20181101288T patent/CY1121431T1/el unknown

Also Published As

Publication number	Publication date
SG10201505038TA (en)	2015-07-30
US9428570B2 (en)	2016-08-30
KR101761929B1 (ko)	2017-07-26
US20160355598A1 (en)	2016-12-08
JP5782385B2 (ja)	2015-09-24
EA037792B1 (ru)	2021-05-21
SG2014014708A (en)	2014-05-29
MA33122B1 (fr)	2012-03-01
AU2010216152A1 (en)	2011-08-18
SG173620A1 (en)	2011-09-29
EP2398498A2 (en)	2011-12-28
IL214282A (en)	2017-04-30
BRPI1008692B1 (pt)	2020-10-27
KR20110128301A (ko)	2011-11-29
CN102741287A (zh)	2012-10-17
US20130330344A1 (en)	2013-12-12
HK1177470A1 (en)	2013-08-23
DK2398498T3 (en)	2019-01-07
CY1121431T1 (el)	2020-05-29
SI2398498T1 (sl)	2019-02-28
EP2398498B1 (en)	2018-09-05
CN102741287B (zh)	2015-02-18
EP2398498A4 (en)	2013-05-01
EA201171060A1 (ru)	2012-07-30
AR075504A1 (es)	2011-04-06
JP2015171362A (ja)	2015-10-01
BRPI1008692B8 (pt)	2021-05-25
US8614295B2 (en)	2013-12-24
NZ594315A (en)	2013-05-31
CL2011001994A1 (es)	2012-02-24
CA2751477A1 (en)	2010-08-26
WO2010096418A2 (en)	2010-08-26
UA107341C2 (uk)	2014-12-25
ZA201105500B (en)	2012-10-31
PE20120211A1 (es)	2012-03-24
TN2011000374A1 (en)	2013-03-27
US10017575B2 (en)	2018-07-10
US20100254978A1 (en)	2010-10-07
HUE042114T2 (hu)	2019-06-28
MX2011008697A (es)	2011-11-18
PL2398498T3 (pl)	2019-03-29
PT2398498T (pt)	2018-12-03
MY157473A (en)	2016-06-15
LT2398498T (lt)	2019-01-10
CO6410312A2 (es)	2012-03-30
TWI476281B (zh)	2015-03-11
JP2012521191A (ja)	2012-09-13
TW201031753A (en)	2010-09-01
HRP20181932T1 (hr)	2019-01-25
CA2751477C (en)	2019-08-27
AU2010216152B2 (en)	2015-05-14
ES2699716T3 (es)	2019-02-12
WO2010096418A3 (en)	2012-06-14
UY32451A (es)	2010-09-30
IL214282A0 (en)	2011-09-27

Publication	Publication Date	Title
BRPI1008692A2 (pt)	2016-03-08	moléculas de anticorpos tendo especificidade para ox40 humano.
LTC2358756I2 (lt)	2022-04-25	Žmogaus antikūnai, pasižymintys dideliu giminingumu pcsk9
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0917204A2 (pt)	2015-12-01	variantes estruturais de anticorpos para melhores características terapêuticas
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
EP2150167A4 (en)	2012-09-05	SEMI-DISPOSABLE ENDOSCOPE
BRPI1015234A2 (pt)	2018-02-20	regiões fc projetadas para conjugação sítio específica.
PT2427212T (pt)	2017-11-20	Anticorpos anti-cd100 e métodos para utilização dos mesmos
BRPI0923159A2 (pt)	2018-08-28	gene de delta-endotoxina axmi-150 e métodos para sua utilização.
BRPI0817273A2 (pt)	2015-06-16	Região constante de anticorpo modificada
EP2207803A4 (en)	2010-11-24	Cd9-specific human antibodies
BRPI0813981A2 (pt)	2017-05-09	agonistas sintéticos da tlr9.
BRPI0817870A2 (pt)	2017-03-28	dispositivo para tratamento de aneurisma
BRPI1014262A2 (pt)	2017-05-23	anticorpos específicos para caderina-17
BRPI0923199A2 (pt)	2016-02-16	métodos e composições para detecção de anticorpos com fixação de complemento.
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
BRPI1008706A2 (pt)	2016-03-08	dispositivo para diagnóstico.
BRPI0923652A2 (pt)	2016-10-18	diagnóstico e tratamento de câncer usando anticorpo anti-lgr7
BRPI0910550A2 (pt)	2015-09-29	ensaio para confôrmeros patogênicos
FR2932448B1 (fr)	2015-12-04	Element de train de roulement.
BRPI1010907A2 (pt)	2016-03-15	emulsão de óleo-em-água.
BRPI0906557A2 (pt)	2015-07-07	Dispositivo de osteossíntese.
FR2927632B1 (fr)	2013-07-19	Cornee et muqueuse reconstruites.
BRPI0813187A2 (pt)	2014-10-14	13-hidroperóxido liases modificadas e respectivos usos.

Legal Events

Date	Code	Title	Description
2017-08-08	B25A	Requested transfer of rights approved	Owner name: UCB BIOPHARMA SPRL (BE)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-06-25	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2020-02-04	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-05-26	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-08-04	B25F	Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement	Owner name: UCB BIOPHARMA SPRL (BE) Free format text: VIDE E-PARECER.
2020-09-29	B25D	Requested change of name of applicant approved	Owner name: UCB BIOPHARMA SRL (BE)
2020-10-27	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/02/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2023-12-12	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 14A ANUIDADE.
2024-04-02	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2762 DE 12-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.